Background. Ferritin and the percentage of transferrin saturation (TS) are established parameters with which to evaluate endogenous iron availability during treatment of renal anaemia with recombinant human erythropoietin (rHuEpo). Zinc protoporphyrin (ZPP) has been proposed as another valid marker in this setting. Methods. We determined the following parameters in 127 patients, including 117 haemodialysis patients: haemoglobin, erythrocytes, haematocrit, mean corpuscular volume (MCV), iron, ferritin, transferrin saturation and ZPP. Of the patients treated in a crosssectional study, 38.5% were treated with rHuEpo; 30.7% with intravenous iron; and 13.6% with intravenous iron and rHuEpo simultaneously. Median ferritin was 304 ng/ml and median transferrin saturation was 21.2%. Results. Including cases with manifest storage iron deficiency, a concordant elevated ZPP (>40 umol/mol haem) and a decreased transferrin saturation (<20%) were found in 23 of our dialysis patients (19.6%) while 55 cases (47%) were classified as concordantly negative. However, as many as 39 cases (33.3%) showed discrepant results: in 16 cases (13.6%) ZPP was elevated but transferrin saturation was in the normal range, while in 23 cases (19.6%) the opposite results were observed. Conclusions. We conclude that beyond the border of manifest storage iron deficiency, defined as a ferritin <30 ng/ml in male and < 15 ng/ml in female patients, ZPP and TS cover different ranges of functional iron deficiency which is reflected in the lack of a correlation of ZPP to any other of the above-mentioned parameters. Our data suggest that a TS <20% as a diagnostic, and thus intervention, criterion in the evaluation of functional iron deficiency and iron substitution beyond manifest storage iron deficiency might result in overestimation of iron requirements. It remains to be shown in a longitudinal study, also reflecting the course of haemoglobin and the mean
Introduction
The introduction of rHuEpo in 1986 for the treatment of anaemia secondary to chronic renal failure significantly enhanced the medical care of patients requiring chronic haemodialysis or equivalent procedures. This therapeutic approach was shown to be effective in mobilizing endogenous iron stores [1] . Both the protection from secondary haemosiderosis related to repeated red blood cell transfusion and the effective treatment of established secondary haemosiderosis can be achieved by this approach. A reduction of the ferritin level by 30% has been reported [2] in end-stage renal disease patients treated with rHuEpo. In long-term management, however, one must anticipate that effective treatment of (functional) iron deficiency will be necessary once body iron stores are depleted.
It is accepted that ferritin is not a very sensitive marker of storage iron deficiency in end-stage renal disease patients. Manifest storage iron deficiency, defined as a ferritin level below 20 ng/ml, may blunt an adequate response to rHuEpo treatment. The estimation of iron with prussian blue staining of a bone marrow smear or a trephine biopsy does not offer an alternative approach because it requires invasive procedures and only provides a semiquantitative assessment of microscopically visable iron (grade 1 to 4). Especially in the subgroup of rHuEpo-treated endstage renal disease patients, a marker of body iron stores may not allow accurate estimation of functional endogenous iron requirements. Some studies have indicated that patients with ferritin levels as low as 100 ng/ml [3] to 150-200 ng/ml [1, 2, 4] should receive exogenous iron. Today, transferrin saturation (TS) below 20% has been established to indicate functional iron deficiency [4, 5] . Recently ZPP was presented as a marker of endogenous iron deficient erythropoiesis in renal, as well as non-renal anaemias [6-13]. In the case of depleted body iron stores or lead intoxication, zinc replaces iron in the protoporphyrin IX ring, which causes the concentration of red blood cell ZPP to rise [10] . In addition to the established parameters, ferritin, transferrin saturation and total iron binding capacity (TIBC), ZPP may be an alternative to evaluate iron metabolism of patients treated with regular haemodialysis. In anaemia due to chronic disease, lowered levels of plasma iron and transferrin saturation are typically found [15] . Hypoferrinaemia in patients with anaemia of chronic disease may also cause reduced iron supply for haemoglobin synthesis and thus elevation of ZPP.
ZPP can be measured fluorometrically. ZPP levels greater than 40 umol/mol haem [8] as well as >80 [14, 16] , have been reported in cases of functional iron deficiency and >90 [6, 7] in end-stage renal disease patients. In a cross-sectional study of predominantly end-stage renal disease patients, we compared these three markers of iron availability. However, when analysing the data, one should keep in mind that there is no global gold-standard for the measurement of functional iron status.
Subjects and methods
Our population of 127 patients included 117 end-stage renal disease patients treated with regular haemodialysis three times weekly. Two of these patients, one with analgesic nephropathy and one with polycystic kidney disease, also suffered from polycythemia vera. In 10 cases without renal anaemia, four had undergone renal transplantation and six exhibited a haematological disorder-one with a myeloproliferative syndrome, three with a myelodysplastic syndrome, one with a stage IV B centroblastic-centrolytic non-Hodgkin lymphoma (NHL) according to Ann Arbor classification, with bone-marrow infiltration, and finally, a female patient with an Evans syndrome resulting from lupus erythematosus.
In a cross-sectional study, we measured the following parameters: haemoglobin, mean corpuscular volume (MCV), plasma iron, transferrin, ferritin and zinc protoporphyrin. Red cell parameters were measured with a Coulter STKS, plasma iron with a Hitachi Multianalyser, transferrin and ferritin with an enzyme immunoassay (EIA). ZPP was measured with the haematofluorometer 206 D, AVIV Biomedical Inc., Lakewood New Jersey. Twenty microlitres of washed erythrocytes [17] were used.
Statistical data analysis was performed using statsoft Statistica. Methods of descriptive statistics were applied. To prevent non-steady-state conditions, patients given iron were treated for at least 3 months before entering the study. In general, the population of dialysis patients had been treated without aluminium containing phosphate binders. In cases with elevated ZPP, determination of plasma aluminium before and after stimulation with a desferrioxamine infusion test showed normal results.
Results
One hundred and twenty-seven patients with a median age of 65 years (20-87 years) were examined. The 487 main causes of renal insufficiency are depicted in Figure 1 . Forty-five of 117 (38.5%) dialysis patients were treated with rHuEpo in a dose range of 1000-14000IU s.c./week (mean 4311 IU). Median haemoglobin was 9.9 g/dl. In 36 of 117 chronic haemodialysis patients (30.8%), renal anaemia was treated with i.v. iron alone, while in 16 patients (13.6%) a simultaneous therapy with rHuEpo and i.v. iron was administered. Table 1 shows the determined parameters of 117 patients with end-stage renal disease. Tables 2 and 3 indicate the same data in the 45 patients treated with rHuEpo. Table 3 includes the 72 patients without rHuEpo therapy. Eight cases with manifest storage iron deficiency, defined as a ferritin level < 30 ng/ml, were detected in our series. This included three female patients, two with a ferritin level < 15 ng/ml and one with a ferritin of 24 ng/ml.
Based on the resulting data we did not find any correlation of peripheral red blood cell parameters to parameters of iron metabolism such as iron, ferritin, transferrin, transferrin saturation and ZPP. As shown in Figure ZPP is of special interest because 66.7% of the values (Table 5) were clear cut and within the normal range (<40 umol/mol haem), while only 32.4% (38/117) were between 40 and 80, suggesting a possible abnormality. Seven of the 127 patients (4.7%) presented with ZPP values > 80 umol/mol haem, which definitely indicates pathology. The data of these seven patients are shown in Table 4 . Only two of these patients were treated with rHuEpo, including one with a transferrin saturation (TS) <20%, but ferritin in the upper normal range and one with a TS >20% and an additional diagnosis of a haemoglobinopathy (thalassaemia). In two other cases with end-stage renal disease, the additional diagnosis of polycythaemia vera required repeated phlebotomies. In these cases, elevation of ZPP can easily be explained by depletion of body iron stores due to the therapeutic procedure. The same pathophysiological mechanism may be postulated in the two other cases with renal transplant and secondary Zinc protoporphyrin as marker of iron availability in HD patients accumulation (siderosis) but normal marrow iron staining (MIG 2+).
The ZPP results are compared to TS in Table 5 . A TS below 20% was found in 39.3% of the dialysis patients and 41.7% of all patients, a TS of 20-45% was observed in 48.7% while only 9.4% (11 cases) presented with a TS above 45% including five patients with intravenous iron supply.
The iron metabolism data, including cases with manifest storage iron deficiency revealed concordant positive results of ZPP (>40 umol/mol haem) and TS (<20%) in 23 cases and concordant negative results in 55 cases (Table 5 ). However, in 39 cases (33.3%) with discrepant results 16 cases (13.6%) showed an elevated ZPP, but normal transferrin saturation while 23 cases (19.6%) presented opposing results (Table 5) . Presuming a TS below 16% as a diagnostic threshold for iron deficiency, the results with normal ZPP are reduced to 17 cases (14.5%). It should be noted that only a slight elevation (^50 umol/mol haem) of ZPP was observed in 11 of 16 cases with ZPP >40 umol/mol haem and normal TS and ferritin.
Discussion
The determination of zinc protoporphyrin to evaluate iron metabolism is easy and inexpensive. However, using the haematofluorometer for this work is a cumbersome process, since samples must be handled individually vial by vial. In our series of dialysis patients, we found only eight cases with clear-cut iron storage deficiency defined as a ferritin level < 30 ng/ml. In cases with non-depleted iron stores, iron-deficient erythropoiesis may occur [18] and this raises the question of whether the iron status is adequately assessed. Transferrin saturation, free erythrocyte protoporphyrin, mean red cell volume, red cell distribution width and serum transferrin receptor have all been proposed [16] as possible parameters to evaluate this condition.
In the majority of cases (Table 5 ) presenting with a ferritin greater than 30 ng/ml (93.1% of all dialysis patients in our series) an abnormal TS (34.1%) was found more often than an elevated ZPP (29.1%). Looking at the discrepancies between the two markers in patients without manifest storage iron deficiency, there are also more cases with an abnormal TS (18.8%) compared to ZPP (13.6%).
Analysis of the data with a box-plot diagram indicates good data quality ( Figure 5 ) and we found no correlation of ZPP to other established parameters of iron metabolism such as ferritin and transferrin saturation in our series. In earlier studies ZPP has been shown to be the best predictor of iron deficiency anaemia in comparison with ferritin or transferrin saturation [10, 11] . In our series 46 dialysis patients (or 53 of all patients) had a transferrin saturation below These different results concerning the sensitivity of ZPP as a predictor of iron deficiency can be explained by different selection of the study population. Zanella et al. [4] reported a striking difference in the diagnostic sensitivity of free erythrocyte protoporphyrin (FEP) in patients with manifest iron deficiency anaemia (>90%) compared to a sensitivity of 50% in those presenting with an isolated depletion of body iron stores. In this study the comparable FEP was also measured fluorometrically. Our study population represents a highly select group of chronic haemodialysis patients who are treated with i.v. iron early on to prevent depletion of body iron stores or iron-deficient erythropoiesis. This is reflected in a median ferritin of 304 ng/ml and median ZPP level of 31 umol/mol haem including all dialysis patients of our series (Table 1) .
Hastka and co-workers [8] analysed subgroups of rHuEpo-treated end-stage renal disease patients and found one group with near normal median ZPP (41.7 umol/mol haem) and ferritin of 278 ng/ml, while the second group showed a ZPP of 82.2 and ferritin of 111 ng/ml. The results observed in our patients were independent of the administration of rHuEpo (Tables  1-3 ) similar to the first group in the series of Hastka. Median ferritin levels and transferrin saturation in our rHuEpo-treated patients were even higher than in the other dialysis patients (Table 3 ). Fishbane and Lynn [7] reported a sensitivity of 90% and a specificity of 87% for ZPP as a diagnostic tool in the evaluation of endogenous iron availability. In comparison, mean corpuscular volume (MCV), defined as <80fl, revealed a sensitivity of only 65% and specificity of 67%. Inferior results also were shown for TS (<20%) with 65 and 63% as well as ferritin (<52 ng/ml) with 75 and 83% [7] . A ZPP level of >90 umol/mol haem was defined as diagnostic for iron storage deficiency by that study. Analysis of our data using this threshold level reveals only seven patients with iron deficiency (Table 4) . This includes four patients subjected to repeated phlebotomies: two because of primary polycythaemia vera and two because of secondary erythrocytosis after renal transplantation; i.e. in the majority of these patients, storage iron deficiency was a result of the therapeutic approach. This leaves three cases including one with non-renal anaemia.
Sixteen cases had a ZPP > 40 and transferrin saturation above 20%. Eleven of these cases only showed a slight increase of ZPP (^50). In two other cases (ZPP 74 and 63) a TS in the lower normal range was found. These data emphasize, in contrast to Hastka et al. [8] , that only ZPP levels > 80 or 90 umol/mol haem should be accepted as diagnostically relevant [7, 15] . The last patient in this subgroup is a female dialysis patient with a ZPP of 114 and a TS of 21.9%. In this patient accompanying thalassaemia can explain the elevation of ZPP without iron deficiency [9, 15, 19] as well as a relative erythropoietin resistance requiring high weekly doses of rHuEpo (Table 4 ). In the patient with NHL M. Baldus et al.
the elevated ZPP and ferritin must be considered as false positive results in the face of normal bone marrow storage iron. In these conditions of anaemia of chronic disease, ZPP and TS cannot be taken as valid markers of functional iron deficiency [9] .
Further subgroup analysis of our series reveals 22 cases with normal ZPP (^40) and decreased TS (<20%). By lowering the diagnostic threshold of transferrin saturation to < 16% as proposed by some groups [1, 15, 16] , the proportion of our false negative ZPP samples is reduced to 17 cases. Compared with transferrin saturation, our data demonstrate that in a selected group of dialysis patients with generous iron supply a diagnostic level of ZPP > 80 or > 90 umol/mol haem does not detect additional cases with manifestly depleted iron stores, or functional iron deficiency anaemia that were overlooked by examination with ferritin or TS. Using the diagnostic level proposed by Hastka [8, 9] , threshold level of ZPP >40 umol/mol haem, 13.6% of our dialysis patients without manifest storage iron deficiency (ferritin > 30 ng/ml) would have been overlooked by measuring ferritin and TS alone.
The clinical relevance of these data cannot be finally determined in a cross-sectional study. Our data favour the idea that early i.v. iron substitution, based on a transferrin saturation <20%, precludes manifest iron deficient erythropoiesis in end-stage renal disease patients. Furthermore, in this select group, at a diagnostic threshold level of > 40 umol/mol haem ZPP, an additional subgroup of patients (13.6%) with normal ferritin and TS was detected. This view is in agreement with the results of studies demonstrating the value of ZPP as a screening marker for iron deficiency [20, 21] .
A gold standard for the determination of functional iron deficiency has not been established. The use of TS <20% may result in overdiagnosis of iron deficiency and unnecessary iron treatment. We discovered that a TS < 20% is questionable if one could show that there is no increase in rHuEpo dose, or a decrease in haematocrit when TS is lower than 20%. Thus Finger and co-workers [22] did not find any correlation between TS, haemoglobin, and rHuEpo dose requirements. They did observe a blunted Epo response with a decrease in haemoglobin only in those patients with a ferritin level < 35 ng/ml. Vice versa, it could be questionable whether the higher rate of patients with a decreased TS (<20%) in our series imply an overestimation of iron deficiency. Finally, this would also imply an iatrogenic iron overload at least of those rHuEpo-treated dialysis patients with i.v. iron supply. Furthermore, Lynn and co-workers [23] investigated two groups of dialysis patients with TS <20% and intravenous iron substitution. Only one group showed a normalization of transferrin saturation and a concomitant 50% decrease in the rHuEpo dose required at the end of the study period. In the other group ferritin levels increased while TS remained less than 20%. Thus, oral and in particular i.v. iron administration in rHuEpo-treated dialysis patients based on TS < 20% may result in overtreatment.
McDougall et al. [24] proposed the use of the proportion of microcytic (<60 fl) and hypochromic (<28 g/dl) red cells, determined by flow cytometry, as another diagnostic parameter to assess iron deficient erythropoiesis in patients with end-stage renal disease receiving rHuEpo treatment. He defined ^2.5% as the diagnostic threshold of microcytic red cells. A combination of appropriate parameters, including the soluble transferrin receptor, may allow a valid discrimination [25] between pure iron deficiency anaemia (IDA) and the anaemia of chronic disease (ACD), both conditions [9] with potentially elevated ZPP. However, such a sophisticated approach is not feasible in routine follow-up.
In conclusion, in our series we did not detect any case of iron deficiency or iron deficiency anaemia by using a ZPP level of > 80 umol/mol haem that was not already detected by using the parameters of ferritin and transferrin saturation. As a result of generous iron supplementation policy, based on a TS <20%, ZPP did not reveal a greater sensitivity than transferrin saturation. Whether ZPP offers an advantage as a reliable and inexpensive follow-up marker at that level or a diagnostic level of > 40 umol/mol haem when handling iron substitution restrictively remains to be shown. Our data favour the assumption that ZPP and TS cover different ranges of storage iron deficiency and iron-deficient erythropoiesis. We suggest that a TS < 20% as an indicator of iron-deficient erythropoiesis may result in overestimation and oversupplementation of iron. In a longitudinal study, the adequacy of the discussed parameters of tissue iron supply could be addressed more properly with regard to the relevant issues of long-term course of haemoglobin and rHuEpo dose in dialysis patients as well.
